CA2902209C - REDUCED TOXICITY PEPTIDES STIMULATING CHOLESTEROL OUTFLOW - Google Patents

REDUCED TOXICITY PEPTIDES STIMULATING CHOLESTEROL OUTFLOW

Info

Publication number
CA2902209C
CA2902209C CA2902209A CA2902209A CA2902209C CA 2902209 C CA2902209 C CA 2902209C CA 2902209 A CA2902209 A CA 2902209A CA 2902209 A CA2902209 A CA 2902209A CA 2902209 C CA2902209 C CA 2902209C
Authority
CA
Canada
Prior art keywords
peptides
polypeptides
cholesterol efflux
apo
parallels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2902209A
Other languages
English (en)
French (fr)
Other versions
CA2902209A1 (en
Inventor
John K Bielicki
Jan Johansson
Waleed Danho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of CA2902209A1 publication Critical patent/CA2902209A1/en
Application granted granted Critical
Publication of CA2902209C publication Critical patent/CA2902209C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
CA2902209A 2013-03-15 2014-03-14 REDUCED TOXICITY PEPTIDES STIMULATING CHOLESTEROL OUTFLOW Active CA2902209C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798191P 2013-03-15 2013-03-15
US61/798,191 2013-03-15
PCT/US2014/029232 WO2014144708A1 (en) 2013-03-15 2014-03-14 Peptides having reduced toxicity that stimulate cholesterol efflux

Publications (2)

Publication Number Publication Date
CA2902209A1 CA2902209A1 (en) 2014-09-18
CA2902209C true CA2902209C (en) 2025-02-04

Family

ID=51537765

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902209A Active CA2902209C (en) 2013-03-15 2014-03-14 REDUCED TOXICITY PEPTIDES STIMULATING CHOLESTEROL OUTFLOW

Country Status (8)

Country Link
US (4) US10017551B2 (enExample)
EP (1) EP2983687B1 (enExample)
JP (1) JP6549554B2 (enExample)
CN (1) CN105050614B (enExample)
AU (1) AU2014228815B2 (enExample)
CA (1) CA2902209C (enExample)
SG (1) SG11201507287SA (enExample)
WO (1) WO2014144708A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105050614B (zh) 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
WO2014197997A1 (en) * 2013-06-14 2014-12-18 University Of Guelph Systems, methods, and computer program products for merging a new nucleotide or amino acid sequence into operational taxonomic units
US11091529B2 (en) 2014-09-17 2021-08-17 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CA3078682A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
SE463651B (sv) 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
GB8408127D0 (en) 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5198208A (en) 1987-07-16 1993-03-30 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
JPH03228046A (ja) 1989-09-13 1991-10-09 Konica Corp 赤外吸収染料を有し経時安定性に優れる写真材料
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
WO1992017215A1 (en) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
GB9006977D0 (en) 1990-03-28 1990-05-23 Nycomed As Compositions
GB9007408D0 (en) 1990-04-02 1990-05-30 Nycomed As Compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US6821287B1 (en) 1991-05-24 2004-11-23 Advanced Cardiovascular Systems, Inc. Multi-mode vascular catheter system
GB9120508D0 (en) 1991-09-26 1991-11-06 Nycomed As Diagnostic agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
WO1993019679A1 (en) 1992-04-07 1993-10-14 The Johns Hopkins University A percutaneous mechanical fragmentation catheter system
FR2699595B1 (fr) 1992-12-23 1995-01-20 Snecma Dispositif de guidage en rotation d'un anneau de commande d'aubes pivotantes.
DE4326466A1 (de) 1993-08-06 1995-02-09 Boehringer Mannheim Gmbh Infrarot-Farbstoff-markierte Nucleotide und ihre Verwendung in der Nucleinsäure-Detektion
AU2076895A (en) 1994-03-28 1995-10-17 Daiichi Pharmaceutical Co., Ltd. Liposomes
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU687093B2 (en) 1994-09-27 1998-02-19 Nycomed Imaging As Contrast agent
CA2175720C (en) 1996-05-03 2011-11-29 Ian M. Penn Bifurcated stent and method for the manufacture and delivery of same
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JP3029976B2 (ja) 1995-01-27 2000-04-10 株式会社コミュータヘリコプタ先進技術研究所 ヘリコプタの動力伝達装置
US5968479A (en) 1995-01-30 1999-10-19 Daiichi Pure Chemicals Co., Ltd. Diagnostic marker
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US6818014B2 (en) 1995-03-01 2004-11-16 Scimed Life Systems, Inc. Longitudinally flexible expandable stent
US6824553B1 (en) 1995-04-28 2004-11-30 Target Therapeutics, Inc. High performance braided catheter
US5717121A (en) 1995-06-07 1998-02-10 Nycomed Salutar, Inc. Preparation and use of contrast agents
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
CA2231425A1 (en) 1995-09-20 1997-03-27 Texas Heart Institute Detecting thermal discrepancies in vessel walls
WO1997025073A2 (en) 1996-01-10 1997-07-17 Nycomed Imaging A/S Contrast media
EA001135B1 (ru) 1996-02-19 2000-10-30 Нюкомед Имагинг А/С Усовершенствования в области контрастных агентов
US6245026B1 (en) 1996-07-29 2001-06-12 Farallon Medsystems, Inc. Thermography catheter
US6391032B2 (en) 1996-08-23 2002-05-21 Scimed Life Systems, Inc. Stent delivery system having stent securement means
US6818016B1 (en) 1997-06-27 2004-11-16 The Regents Of The University Of Michigan Methods for coating stents with DNA and expression of recombinant genes from DNA coated stents in vivo
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6827730B1 (en) 1998-01-13 2004-12-07 Endovascular Technologies, Inc. Reduced diameter stent/graft deployment catheter
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
US6368315B1 (en) 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US6829497B2 (en) 1999-09-21 2004-12-07 Jamil Mogul Steerable diagnostic catheters
US6254631B1 (en) 1999-09-23 2001-07-03 Intratherapeutics, Inc. Stent with enhanced friction
DE19951477A1 (de) 1999-10-26 2001-05-03 Biotronik Mess & Therapieg Stent
US6827703B1 (en) 1999-11-24 2004-12-07 Coopersurgical, Inc. Single lumen balloon catheter apparatus
JP4263826B2 (ja) 1999-11-26 2009-05-13 テルモ株式会社 カテーテルの製造方法およびカテーテル
US6254593B1 (en) 1999-12-10 2001-07-03 Advanced Cardiovascular Systems, Inc. Bifurcated stent delivery system having retractable sheath
US6537311B1 (en) 1999-12-30 2003-03-25 Advanced Cardiovascular Systems, Inc. Stent designs for use in peripheral vessels
US6475210B1 (en) 2000-02-11 2002-11-05 Medventure Technology Corp Light treatment of vulnerable atherosclerosis plaque
ATE255860T1 (de) 2000-03-03 2003-12-15 Cook Inc Endovaskuläre vorrichtung mit stent
US6818247B1 (en) 2000-03-31 2004-11-16 Advanced Cardiovascular Systems, Inc. Ethylene vinyl alcohol-dimethyl acetamide composition and a method of coating a stent
US6821296B2 (en) 2000-06-05 2004-11-23 Theragenics Corporation Device for delivering a radioactive and/or drug dosage alone or in connection with a vascular stent
US6805704B1 (en) 2000-06-26 2004-10-19 C. R. Bard, Inc. Intraluminal stents
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6802857B1 (en) 2000-10-11 2004-10-12 Uab Research Foundation MRI stent
US6565599B1 (en) 2000-12-28 2003-05-20 Advanced Cardiovascular Systems, Inc. Hybrid stent
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US6821291B2 (en) 2001-06-01 2004-11-23 Ams Research Corporation Retrievable stent and method of use thereof
US6818013B2 (en) 2001-06-14 2004-11-16 Cordis Corporation Intravascular stent device
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
NL1019540C2 (nl) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
US6805707B1 (en) 2001-12-27 2004-10-19 Advanced Cardiovascular Systems, Inc. Stent with improved ring and link pattern
US7691965B2 (en) 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US6802859B1 (en) 2002-07-12 2004-10-12 Endovascular Technologies, Inc. Endovascular stent-graft with flexible bifurcation
US6819951B2 (en) 2002-09-24 2004-11-16 Mayo Foundation For Medical Education And Research Peripherally inserted central catheter with continuous central venous oximetry and proximal high flow port
US20050159362A1 (en) * 2003-04-22 2005-07-21 Sircar Jagadish C. Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US7118567B2 (en) 2003-04-30 2006-10-10 Medtronic Vascular, Inc. Method for treating vulnerable plaque
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
PT2332968T (pt) 2003-11-05 2016-08-17 Harvard College Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular
BRPI0513402A (pt) 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
AU2007304847A1 (en) * 2006-10-04 2008-04-10 Inimex Pharmaceuticals, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
CA2672131C (en) * 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux
RU2011101536A (ru) * 2008-06-18 2012-07-27 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us) Усовершенствованные пептидные медиаторы оттока холестерина
EP2517013A4 (en) * 2009-12-23 2013-07-17 Artery Therapeutics Inc DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT
WO2011139819A2 (en) 2010-04-28 2011-11-10 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
CN105050614B (zh) 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽

Also Published As

Publication number Publication date
AU2014228815A1 (en) 2015-09-03
US20140287994A1 (en) 2014-09-25
US11434267B2 (en) 2022-09-06
CA2902209A1 (en) 2014-09-18
EP2983687B1 (en) 2019-09-04
EP2983687A4 (en) 2016-11-16
US20210171586A1 (en) 2021-06-10
WO2014144708A1 (en) 2014-09-18
US10774118B2 (en) 2020-09-15
JP6549554B2 (ja) 2019-07-24
CN105050614B (zh) 2019-04-05
US20160031951A1 (en) 2016-02-04
JP2016516054A (ja) 2016-06-02
AU2014228815B2 (en) 2019-04-18
US9416162B2 (en) 2016-08-16
CN105050614A (zh) 2015-11-11
US20180298066A1 (en) 2018-10-18
EP2983687A1 (en) 2016-02-17
SG11201507287SA (en) 2015-10-29
US10017551B2 (en) 2018-07-10

Similar Documents

Publication Publication Date Title
CA2902209C (en) REDUCED TOXICITY PEPTIDES STIMULATING CHOLESTEROL OUTFLOW
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
WO2014204816A3 (en) Method for assessing protein identity and stability
SG10201909796PA (en) Chemosensory receptor ligand-based therapies
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012054526A8 (en) Chemosensory receptor ligand-based therapies
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012138599A3 (en) Hepatocyte growth factor mimics as therapeutic agents
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2009155366A3 (en) Improved peptide mediators of cholesterol efflux
BR112014024964A8 (pt) formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação
Zumbansen et al. Recent advances in the treatment of post-stroke aphasia
EE05761B1 (et) Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks
WO2014058979A8 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
WO2012054527A3 (en) Chemosensory receptor ligand-based therapies
WO2009111611A3 (en) Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
WO2012065153A3 (en) Modified immune-modulating particles
WO2015025226A3 (en) Compositions and therapeutic methods for accelerated plaque regression
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2012054528A3 (en) Chemosensory receptor ligand-based therapies
WO2012054530A3 (en) Chemosensory receptor ligand-based therapies
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
Kim et al. Levetiracetam‐induced thrombocytopenia in a patient with status epilepticus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190312

EEER Examination request

Effective date: 20190312

EEER Examination request

Effective date: 20190312

EEER Examination request

Effective date: 20190312

EEER Examination request

Effective date: 20190312

EEER Examination request

Effective date: 20190312

EEER Examination request

Effective date: 20190312

EEER Examination request

Effective date: 20190312